Callan Jmb INC

Callan JMB Inc. received a notice from Nasdaq for failing to meet the minimum bid price requirement, with 180 days to regain compliance.

Callan JMB Inc. announced the resignation of Executive Vice President Eric Kash, detailing a severance package and outstanding stock options.

Callan JMB Inc. received a deficiency letter from Nasdaq for failing to meet the minimum stockholders equity requirement, with a plan to regain compliance due by May 22, 2026.

Callan JMB Inc. announced its full year 2025 financial results, reporting a decrease in revenue and a significant increase in operating loss, while highlighting strategic growth initiatives in healthcare and emergency preparedness.

Callan JMB Inc. has amended its common stock purchase agreement with Hexstone Capital, LLC, extending the maturity date and revising key terms for future equity sales.

Callan JMB Inc. announced it will commence a series of investor presentations at the DealFlow Discovery Conference starting January 28, 2026.

Callan JMB Inc. reported a significantly wider net loss for the third quarter and first nine months of 2025, driven by increased operating expenses and costs associated with its new Equity Line of Credit facility.

Callan JMB Inc. posted a significantly increased net loss for the second quarter and first half of 2025, primarily due to decreased specialty packaging revenue and a substantial rise in administrative expenses.

Callan JMB Inc.'s Q1 2025 revenue decreased by 19% year-over-year, while operating expenses significantly increased, leading to a substantial net loss.

Callan JMB Inc. reported a significant net loss of $7.97 million for 2025, a substantial increase from the prior year, alongside a 13% drop in revenue.

Callan JMB Inc.'s 2024 10-K filing reveals a decrease in revenue compared to 2023, alongside strategic shifts towards new market opportunities and enhanced cost management.

Callan JMB Inc. director Gerald Dial reported transactions involving common stock and stock options, including the acquisition of 10,000 shares and the grant of an option to purchase 25,000 shares.

CALLAN JMB Inc. Director and Chief Medical Officer David J. Croyle acquired 10,195 shares of common stock at $1.75 per share.

CALLAN JMB Director Gerald Dial reported acquiring 2,000 shares of common stock and holding 25,000 stock options.

CALLAN JMB INC. CEO, Chairman, and President Wayne D. Williams purchased 5,000 shares of common stock at $1.73 per share.

CALLAN JMB INC. CEO Wayne D. Williams filed a Form 4 disclosing planned common stock purchases in December 2025 under a Rule 10b5-1 trading plan.

CALLAN JMB CEO Wayne D. Williams acquired additional common stock through indirect holdings in December 2025.

Callan JMB Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on December 29, 2025, to elect directors and ratify its independent auditor.

Callan JMB Inc. has secured an Equity Line of Credit for up to $25 million with Hexstone Capital LLC, approved by majority stockholders to fund operations and growth.

Callan JMB Inc. filed an S-1/A amendment, revealing a new $25 million equity purchase agreement with Hexstone Capital, LLC and a related registration rights agreement.

Callan JMB Inc. filed an S-1 registration statement for the resale of up to 6 million shares by Hexstone Capital, LLC, while reporting significant revenue declines and increased net losses for the first half of 2025.

Callan JMB Inc. has filed an amendment to its registration statement for an initial public offering of 1,280,000 shares of common stock, with an expected price between $4.00 and $6.00 per share.

Callan JMB Inc. has filed an Underwriters Warrant Agreement and an amendment to its S-1 registration statement, detailing terms for its upcoming initial public offering.

Callan JMB Inc. has filed an amendment to its registration statement for a proposed initial public offering of 1,280,000 shares of common stock, with an expected price between $4.00 and $6.00 per share.

Callan JMB Inc. has filed an amendment to its S-1 registration statement, detailing the terms of underwriter warrants and other aspects of its upcoming initial public offering.

Bard Associates, Inc. has filed a Schedule 13G, reporting beneficial ownership of 239,266 shares, representing 4.3% of the outstanding common stock of Callan JMB Inc.

Investment adviser Bard Associates Inc. has disclosed a 5.3% beneficial ownership stake in Callan JMB Inc. common stock.

Ionic Ventures, Ionic Management, Brendan O'Neil, and Keith Coulston have filed an exit statement, confirming they no longer beneficially own any shares of Callan JMB Inc. Common Stock.

Bard Associates Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 9.3% of CALLAN JMB INC.'s common stock as of February 5, 2025.

Bard Associates Inc. has filed a Schedule 13G, revealing a beneficial ownership of 9.3% of Callan JMB Inc.'s common stock.

A group led by Ionic Ventures, LLC, including Ionic Management, LLC, Brendan O'Neil, and Keith Coulston, has reported a 5.5% beneficial ownership stake in Callan JMB Inc. following its initial public offering.